Paul Clancy - Incyte Director
| INCY Stock | USD 51.74 0.09 0.17% |
Director
Mr. Paul J. Clancy is an Independent Director of Incyte Corporationrationration. Mr. Clancy has more than 30 years of experience in financial management and strategic business planning, and has served as the Executive Vice President and Chief Financial Officer of Alexion Pharmaceuticals, Inc., a biopharmaceutical company, since July 2017. Prior to joining Alexion, Mr. Clancy served as Executive Vice President, Finance and Chief Financial Officer of Biogen Inc., a biotechnology company, from August 2007 until June 2017. He also served as Senior Vice President of Finance of Biogen, with responsibilities for leading the treasury, tax, investor relations and business planning groups. Prior to the 2003 merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation to form Biogen, Mr. Clancy was the Vice President of Portfolio Management of Biogen. He joined Biogen in 2001 as Vice President of U.S. Marketing. Before Biogen, Mr. Clancy spent 13 years at PepsiCo Inc., a food and beverage company, serving in a variety of financial and general management positions, including Vice President and General Manager of their Great West Business Unit. since 2015.
| Age | 56 |
| Tenure | 9 years |
| Address | 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803 |
| Phone | 302 498 6700 |
| Web | https://www.incyte.com |
Incyte Management Efficiency
The company has return on total asset (ROA) of 0.0646 % which means that it generated a profit of $0.0646 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.125 %, meaning that it created $0.125 on every $100 dollars invested by stockholders. Incyte's management efficiency ratios could be used to measure how well Incyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.1 in 2024. Return On Capital Employed is likely to rise to 0.12 in 2024. At this time, Incyte's Return On Assets are fairly stable compared to the past year.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Giles Kerr | Adaptimmune Therapeutics Plc | 56 | |
| Allison JeynesEllis | Agenus Inc | 52 | |
| Lawrence Alleva | Adaptimmune Therapeutics Plc | 68 | |
| Ulf Wiinberg | Agenus Inc | 59 | |
| Gary Bridger | X4 Pharmaceuticals | N/A | |
| Viviane Monges | ADC Therapeutics SA | 57 | |
| Angus Forrest | Terns Pharmaceuticals | N/A | |
| Barbara Duncan | Adaptimmune Therapeutics Plc | 53 | |
| Ian Laing | Adaptimmune Therapeutics Plc | 68 | |
| Wadih Jordan | Agenus Inc | 83 | |
| Bruce Leith | Terns Pharmaceuticals | N/A | |
| Peter Thompson | Corvus Pharmaceuticals | 56 | |
| Scott Morrison | Corvus Pharmaceuticals | 60 | |
| Timothy Wright | Agenus Inc | 60 | |
| David Mott | Adaptimmune Therapeutics Plc | 52 | |
| Paul Blackburn | Mereo BioPharma Group | 61 | |
| Ali Behbahani | Adaptimmune Therapeutics Plc | 40 | |
| Shahzad Malik | Agenus Inc | 46 | |
| Tyrell Rivers | ADC Therapeutics SA | 48 | |
| Ian Clark | Corvus Pharmaceuticals | 57 | |
| Steve Krognes | Corvus Pharmaceuticals | 49 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0646 |
Incyte Leadership Team
Elected by the shareholders, the Incyte's board of directors comprises two types of representatives: Incyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Incyte. The board's role is to monitor Incyte's management team and ensure that shareholders' interests are well served. Incyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Incyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Stein, Senior Vice President and Chief Medical Officer | ||
| Paul Trower, Principal Accounting Officer and VP of Fin. | ||
| Thomas Tray, Chief Finance | ||
| Pamela Murphy, Vice Communications | ||
| Eric Siegel, Executive Vice President General Counsel | ||
| Vijay Iyengar, Executive Vice President Global Strategy and Corporate Development` | ||
| Reid Huber, Chief Scientific Officer and Executive VP | ||
| Richard Levy, Executive Vice President Chief Drug Development and Medical Officer | ||
| Christine Chiou, Head Relations | ||
| PharmD MBA, Executive America | ||
| JeanJacques Bienaime, Independent Director | ||
| Paul Brooke, Independent Director | ||
| Maria Pasquale, Executive Vice President General Counsel | ||
| Christiana Stamoulis, CFO, Executive Vice President | ||
| Steven MD, Executive Officer | ||
| Julian Baker, Independent Vice Chairman of the Board | ||
| Sheila Denton, Executive Counsel | ||
| Michael Booth, VP - Investor Relations | ||
| David Gryska, CFO, Executive Vice President | ||
| Paul Friedman, Director | ||
| Wenqing Yao, Executive Vice President - Discovery Medicinal and Process Chemistry | ||
| Jacqualyn Fouse, Director | ||
| Paula Swain, Executive Resources | ||
| Paul Clancy, Director | ||
| Wendy Dixon, Independent Director | ||
| Michael Morrissey, Executive Operations | ||
| Herve Hoppenot, Chairman, CEO and President and Member of Non-Management Stock Option Committee | ||
| Barry Flannelly, Executive Vice President - Business Development and Strategic Planning | ||
| Dashyant Dhanak, Executive Vice President Chief Scientific Officer | ||
| Christiana MBA, Executive CFO | ||
| Maria JD, Gen VP | ||
| MBA MBA, Ex America |
Incyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Incyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0646 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 7.99 B | ||||
| Shares Outstanding | 224.53 M | ||||
| Shares Owned By Insiders | 1.58 % | ||||
| Shares Owned By Institutions | 99.96 % | ||||
| Number Of Shares Shorted | 8.06 M | ||||
| Price To Earning | 19.17 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.Note that the Incyte information on this page should be used as a complementary analysis to other Incyte's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Incyte Stock analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stocks Directory Find actively traded stocks across global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |
Is Incyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Incyte. If investors know Incyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Incyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.324 | Earnings Share 2.65 | Revenue Per Share 16.526 | Quarterly Revenue Growth 0.093 | Return On Assets 0.0646 |
The market value of Incyte is measured differently than its book value, which is the value of Incyte that is recorded on the company's balance sheet. Investors also form their own opinion of Incyte's value that differs from its market value or its book value, called intrinsic value, which is Incyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incyte's market value can be influenced by many factors that don't directly affect Incyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Incyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.